Celcuity (CELC) Is Down 17.4% After FDA Clears First-in-Class REVTORPYK Combo for HR+ Breast Cancer
Celcuity (Nasdaq: CELC) said the FDA approved REVTORPYK (gedatolisib) with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation after at least one endocrine therapy line. The VIKTORIA-1 data showed a progression-free survival benefit, with higher stomatitis, rash and metabolic side effects. The stock was reported down 17.4%.
How this was made
The 30-second read
Why it matters
The approval is first-in-class for targeting all class I PI3K isoforms and both mTORC1 and mTORC2 complexes in this biomarker-defined group, but the article emphasizes a high side-effect incidence and frames the next hurdle as real-world uptake and payer access.
Market read
Traders should weigh regulatory de-risking against commercialization friction (adoption, pricing, payer coverage) and tolerability-driven real-world effectiveness.
What to watch
The article notes VIKTORIA-1 progression-free survival benefit but also a high incidence of stomatitis, rash, and metabolic side effects, which may drive dosing, discontinuation, and formulary decisions more than efficacy alone.
Background
Celcuity’s REVTORPYK (gedatolisib) received FDA approval in combination with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation after at least one line of endocrine therapy in the metastatic setting.
Ticker impact
Celcuity shares fell 17.4% after the FDA cleared REVTORPYK (gedatolisib) plus fulvestrant, with or without palbociclib, for HR+/HER2- metastatic breast cancer without PIK3CA mutation.
Near-term volatility likely remains elevated as the market digests uptake, pricing, and side-effect burden (stomatitis, rash, metabolic effects).
The article provides a concrete regulatory approval and the observed sharp selloff, plus specific adverse-event categories and a shift in the next key catalyst to real-world adoption and payer coverage.
Market effects
Reinforces competitive intensity in PI3K/mTOR pathway oncology and highlights tolerability as a key commercialization gating factor for targeted combos.
Primarily US biotech sentiment via FDA label expansion for HR+/HER2- breast cancer.
Could influence global PI3K combo development and payer discussions for similar biomarker-defined populations.
Counterpoint
The approval resolves near-term regulatory risk; the selloff may be over-discounting early adoption and could reverse if real-world uptake and access prove stronger than feared.
Key entities
- companyCelcuity
Nasdaq-listed clinical-stage biotech; subject of the article and the stock move.
- drugREVTORPYK (gedatolisib)
FDA-cleared first-in-class PI3K/mTOR combo therapy in HR+/HER2- metastatic breast cancer without PIK3CA mutation.
- drugfulvestrant
Endocrine therapy used in combination with REVTORPYK in the approved regimen.
- drugpalbociclib
CDK4/6 inhibitor included as an optional component of the approved combination.
- clinical trialVIKTORIA-1
Trial cited for progression-free survival benefit, alongside reported tolerability issues.
